(265) a. A: Many small and large interests (26 + 27/11)

APOTIMATAI to 624.4 million euros
Share price: 1.6640 euros
Price multiple to 9 months: 3.85
EV/EBITDA 9 million: 5.7
Net loan: 1.045 billion
Leverage ratio: 1.03
sales! 2.9 billion euros
Book value: 2.7100 euros
Net position: 1.017 billion euros
Earnings per share: 0.4337 (9 million)
With a p/e of 7, the valuation will be on the board at €3.0500…

• Currently, the ELVAL plant is the most modern hot-rolling plant in the world, which allows the group to be among the 4 largest production plants in Europe and among the 20 worldwide.

In the last decade, the Group has implemented total investments in excess of €700m, with €557m achieved in the last four years.

APOTIMATAI to 485.7 million euros

Share price: 4.5300 euros

Net position: 229 million euros

Book value: 2.1400 euros

P/E 9M: 15

EV/EBITDA 9M: 10

Available cash: 100.5 million euros

Loan: 158 million euros

Net loan: 57.5 million

Leverage ratio: 0.25

Negative cash flows 36.8 million

Dividend yield (estimated for the current year): 4.25

Manos Hatzidakis: In the 42 companies that reported 9-month results, the increase in turnover was 69% (52.6 billion euros), operating profit 7.1 billion euros (+51.9%) and net profit 6.5 billion euros (+340). %).

• 90% of businesses are profitable, with performance positively charged by the energy sector’s outperformance, but also an exceptional tourism year.

It seems that the listed companies will break the historical record for net profit of 2007 (7.9 billion euros) this year, because in addition to the strong growth recorded in economic indicators, the low tax rate gives more incentives to show real companies. performance, unlike in the past, which in turn translates to more tax revenue and greater degrees of financial freedom.

Very informative article From Chameleon answers some of our readers’ questions about the infamous AMK from LAVIPHARM…

Basins: The prospectus for Lavipharm’s IPO has been approved by the Capital Market Commission, however Warnings Mentioned quite a few.

For example, if an issue is covered by only major contributors, it will come up working capital deficit Within the next twelve months, at which point, the company will be required to issue a new bond loan of €15 million, and if it fails to do so, proceed with the sale of real estate or other assets.

• Also, any coverage of the issue by only major contributors would reduce it to very low levels free float of stocks at AX.

Another important point related to the expected performance of Lavipharm which is talking about its pre-discount turnover and going back to 112.5 million in 2026.

• The European Commission notes that these predictions may prove correct inaccurateparticularly in terms of the sales targets that will come from the purchased clonidine patch and medicinal cannabis products.

The leaflet also mentions how clonidine is valued at 42.5 million euros, of which 34 million will be the participation of major shareholders in the next IPO and for the remaining 8.5 million Lavida will collect 10% of net sales in Italy.

• Therefore, in practice, the assessment was carried out only by the chartered accountant, and in fact with the data provided to him by the company and which he himself Can’t rate!!! It is indicated that in order to derive the fair value, projections from 2022 to 2044 were used !!!!!!!!!!!!

Finally, the specific drug is scheduled to arrive in Greece and other European countries from 2025 onwards.

PPC: Without making substantial news, its stock continues to trend. We now stop at the daily close at 6.2100 euros…it is trying to stay above the 200 level.

• A close above €6.6600 could give continuation with our next important target being the €7.0400-€7.1800 area. A level that is also 38% of its entire downward move. (Elias Zacharakis)

Elha: We saw it early on and it has now distributed 30% of its bottoms. The investments it has made and continues to make have helped it move from record to record in results.

• Within a week, it has the nearest resistance at 1.6600 EUR and as a next target 1.8000 EUR. 1.5600 EUR is the near support and the aggressive trend (Ilias Zacharakis)

Update – Management Committee of the Athens Stock Exchange During yesterday’s meeting, he approved the following organizational changes:

1. A change in the reference price for calculating the closing price in shares belonging to the first two levels of trading activity, i.e., high trading activity (HTY) and medium trading activity (HTY) in the main market.

• In particular, it will be taken as its reference value Closing auctionthe block-weighted average (SMO) of the transactions made in the last 30 minutes, before the end of the session.

2. A change in the minimum limits for pre-agreed deals in the derivatives market, which will now be calculated on the basis of the value and not the size of the contracts. In particular, the minimum value for derived beams will be:

· GR_INDEX DERIVATIVES (Market ID: 1) / 50.000 in the index FTSE / ATHEX BIG HAT

GR_STOCK derivatives (market ID: 2) / 50.000 in equity derivatives

· GR_INDEX DERIVATIVES (MARKET ID: 1) / 200.000 in the index FTSE/XA banks – DTP

Avax: With the sale of part of Volterra’s RES portfolio to PPC Renewables months ago, and with the divestment of GEFYRA SA, the group has officially closed the sales cycle. The three sales, namely the Group offices, RES, Bridge at a total price of 153.5 million euros, at a historical cost of 61.2 million euros, brought the group a profit of 92.3 million euros.

• At the same time, importance is given to the signing of the contract and start-up of the works for the PPP project for the new eastern ring road in Thessaloniki (also known as FlyOver, with a budget of 462 million euros) which will be implemented by AVAX SA – Mytilineos SA and the signing of the Bralos section road contract – Amfissa from the diagonal axis Lamia – Itea – Antirrio.

Avax (1) – Yesterday’s announcement: The signatures for the Paliovarsalos-Kalambaka railway line have been signed. The project contractor is AVAX SA. The contractual price is 52.2 million euros.

• Capital: 110 million euros.
• Under observation